Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.
Kittelson JM, Steg PG, Halperin JL, Goldenberg NA, Schulman S, Spyropoulos AC, Kessler CM, Turpie AG, Cutler NR, Hiatt WR.
Multicenter Randomized Controlled Trial on Duration of Therapy for Thrombosis in Children and Young Adults (Kids-DOTT): Pilot/Feasibility Phase Findings.
Goldenberg NA, Abshire T, Blatchford PJ, Fenton LZ, Halperin JL, Hiatt WR, Kessler CM, Kittelson JM, Manco-Johnson MJ, Spyropoulos AC, Steg PG, Stence NV, Turpie AG, Schulman S; Kids-DOTT Trial Investigators.
Balancing Risk and Benefit in Venous Thromboembolism Trials: Concept for a Bivariate Endpoint Trial Design and Analytic Approach.
Kittelson JM, Spyropoulos AC, Halperin JL, Kessler CM, Schulman S, Steg G, Turpie AG, Cutler NR, Hiatt WR, Goldenberg NA; Antithrombotic Trials Leadership and Steering (ATLAS) Group.
Comparative effectiveness and safety of the novel oral anticoagulants: Do the pivotal clinical trials point to a new paradigm?
Spyropoulos AC, Goldenberg NA, Kessler CM, Kittelson J, Schulman S, Turpie AG, Cutler NR, Hiatt WR, Halperin JL; Antithrombotic Trials Leadership and Steering Group (ATLAS).
The ATLAS Group designs and leads the next generation of antithrombotic clinical trials, while providing highly engaged expertise in leading protocol design, developing and implementing quality endpoint programs across the spectrum of thrombosis-related and bleeding-related outcome measures, providing independent interpretation of study findings, and leading presentations and publications of trial results.